Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy (Re-Check)
Clinical trial NCT05383001 · WITHDRAWN
Trial details
- NCT number
- NCT05383001
- Sponsor
- AIO-Studien-gGmbH
- Status
- WITHDRAWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-05-20
- Primary completion
- 2026-05-01
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.